Pharming Group (NASDAQ:PHAR) Earns “Outperform” Rating from Oppenheimer

Pharming Group (NASDAQ:PHAR)‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a note issued to investors on Friday,Benzinga reports. They presently have a $41.00 target price on the stock, down from their previous target price of $42.00. Oppenheimer’s target price would indicate a potential upside of 176.47% from the stock’s previous close.

A number of other brokerages also recently issued reports on PHAR. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. HC Wainwright set a $37.00 price target on Pharming Group and gave the company a “buy” rating in a report on Thursday. Wall Street Zen raised Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Finally, Zacks Research downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Pharming Group Stock Down 2.0%

PHAR stock traded down $0.31 during midday trading on Friday, hitting $14.83. The company’s stock had a trading volume of 20,598 shares, compared to its average volume of 29,159. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35. Pharming Group has a 12 month low of $7.50 and a 12 month high of $21.34. The company has a market cap of $1.04 billion, a PE ratio of -1,481.52 and a beta of 0.04. The firm’s 50-day moving average is $17.26 and its 200-day moving average is $16.05.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08). The firm had revenue of $106.50 million during the quarter, compared to analysts’ expectations of $111.76 million. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%. On average, equities research analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A number of large investors have recently bought and sold shares of the business. NewEdge Advisors LLC raised its stake in shares of Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Pharming Group in the fourth quarter valued at about $360,000. SmartHarvest Portfolios LLC bought a new stake in shares of Pharming Group in the fourth quarter valued at about $224,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Pharming Group in the second quarter worth about $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Key Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $37 price target on PHAR, and projects FY2026 EPS of $0.35 (supportive sentiment from a well-known boutique healthcare analyst).
• Neutral Sentiment: Pharming reaffirmed its 2026 guidance and reported Q4 revenue of $106.5M — the guidance confirmation reduces downside risk even though revenue was slightly below consensus. Pharming Group reports Q4 revenue of $106.5m, reaffirms 2026 guidance
• Neutral Sentiment: Earnings call transcript and company materials (press release and slide deck) are available — useful for investors digging into margin drivers, product uptake and 2026 guidance details. Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript Press Release
• Neutral Sentiment: Coverage pieces previewing the quarter and noting increased pipeline investment highlight that R&D spend and pipeline execution are near-term focus areas; these can swing sentiment depending on upcoming milestones. Pharming earnings on deck as pipeline investment ramps up
• Negative Sentiment: Q4 EPS of $0.07 missed the consensus $0.15 estimate and revenue ($106.5M) came in below the ~$111.8M consensus — an earnings miss that likely pressured the share price. Pharming Q4 earnings report
• Negative Sentiment: HC Wainwright trimmed its FY2026 EPS forecast from $0.49 to $0.35 — a downward revision that signals tempered near-term profitability expectations even though the firm retained a Buy stance.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.